Concomitant administration of simvastatin and danazol associated with fatal rhabdomyolysis
article
OA: closed
CC0
⤵ 1 in-corpus citation
AI-generated summary
This case report describes a fatal instance of rhabdomyolysis in a patient who was concomitantly administered simvastatin and danazol.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
BackgroundSimvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, is indicated for the treatment of hypercholesterolemia and plays an important role in both the primary and secondary prevention of cardiovascular disease. Danazol is a steroid analogue approved for the treatment of endometriosis, fibrocystic breast disease, and hereditary angioedema. Despite not being licensed, danazol has been used for other off-label indications, such as idiopathic thrombocytopenic purpura (ITP), paroxysmal nocturnal hemoglobinuria, and aplastic anemia.ObjectiveWe report a case of fatal rhabdomyolysis that occurred after concomitant administration of simvastatin and danazol in a patient with ITP.Case summaryAn 80-year-old white male (height, 182 cm; weight, 90 kg) presented to the emergency department of the Clinical Hospital Centre Zemun, Belgrade, Serbia, with head injuries after an accidental fall caused by generalized weakness. He denied other complaints, except fatigue, mild pretibial edema, and progressive bilateral leg pain and cramping that began 7 days before. At the time of presentation, he was receiving aspirin 100 mg/d, clopidogrel 75 mg/d, ramipril 2.5 mg/d, pantoprazole 40 mg/d, danazol 600 mg/d, prednisone 60 mg/d, simvastatin 40 mg/d, and long-acting insulin 24 IU/d. After the injuries were treated, he was diagnosed with collapse and nasal contusion, and discharged without any changes in his therapy. Two days after initial presentation, the patient was readmitted to the hospital due to nausea, dark urine, and oliguria. All clinical signs (oliguria, dark urine, muscle pain, and tenderness) and laboratory markers (creatine kinase levels approximately 100 times the upper limit of normal, along with hyperkalemia, hyperphosphatemia, and hypoalbuminemia) were consistent with severe rhabdomyolysis. Despite intravenous hydration, forced diuresis, and hemodialysis, oliguria persisted and the patient died 6 days after admission. A score of 5 on the Naranjo adverse drug reaction probability scale was consistent with a probable association of rhabdomyolysis and concomitant treatment with simvastatin and danazol in this patient.ConclusionsStatin-induced rhabdomyolysis must be considered whenever muscle or motor symptoms occur, especially when concomitant treatment with known inhibitors of statin metabolism is administered. Patients must be strictly monitored and the statin should be promptly discontinued with the onset of first signs and symptoms of myopathy. Clinicians should be aware of the potentially fatal consequences of both approved and unapproved treatments and be alert for the early detection of toxicity.
My notes (saved in your browser only)
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (29)
- Danazol for paroxysmal nocturnal hemoglobinuria via openalex
- Danazol therapy for aplastic anemia refractory to immunosuppressive therapy via openalex
- Efficacy of Danazol in Hematologic Disorders via openalex
- Impairment of CYP3A4 Capacity in Patients Receiving Danazol Therapy: Examination on Oxidative Cortisol Metabolism via openalex
- Potential drug interaction between simvastatin and danazol causing rhabdomyolysis. via openalex
- [Severe rhabdomyolysis in a patient receiving lovastatin, danazol, and doxycycline]. via openalex
- doi:10.1182/blood-2009-06-225565 via openalex
- doi:10.1177/0091270002042012008 via openalex
- doi:10.1016/s0149-2918(08)80058-6 via openalex
- doi:10.1001/jama.289.13.1652 via openalex
- doi:10.1038/sj.bjp.0703920 via openalex
- doi:10.1182/blood.v88.1.3.bloodjournal8813 via openalex
- doi:10.1016/j.ddstr.2004.09.005 via openalex
- doi:10.1002/pds.1711 via openalex
- doi:10.1002/mc.2940130302 via openalex
- doi:10.1046/j.1365-2141.2003.04131.x via openalex
- doi:10.1038/clpt.1981.154 via openalex
- doi:10.1046/j.1365-2125.2003.01720.x via openalex
- doi:10.1001/jama.289.13.1681 via openalex
- doi:10.1007/s11095-005-9371-5 via openalex
- doi:10.1016/j.jemermed.2005.08.020 via openalex
- doi:10.7326/0003-4819-130-6-199903160-00002 via openalex
- doi:10.2165/00002018-200225090-00004 via openalex
- doi:10.1007/s00059-010-3262-1 via openalex
- W80404519 via openalex
- doi:10.1592/phco.26.11.1601 via openalex
- doi:10.1023/a:1018877803319 via openalex
- doi:10.7326/0003-4819-114-4-342_1 via openalex
- doi:10.1111/j.1472-8206.2009.00757.x via openalex
Cited by (1)
- Danazol 2022
Source provenance
- europepmc
- last seen: 2026-08-01T06:07:04.264727+00:00
- openalex
- last seen: 2026-05-11T06:40:38.933960+00:00
- pubmed
- last seen: 2026-05-13T22:17:07.008521+00:00
License: CC0
· commercial use OK